World Investment Advisors LLC Invests $1.61 Million in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

World Investment Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 33,249 shares of the company’s stock, valued at approximately $1,614,000. World Investment Advisors LLC owned about 0.07% of Amphastar Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after acquiring an additional 273 shares in the last quarter. Innealta Capital LLC bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $55,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the last quarter. Blue Trust Inc. grew its position in Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares in the last quarter. Finally, Asset Management One Co. Ltd. purchased a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at about $78,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 5.1 %

Shares of AMPH opened at $42.24 on Friday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92. The stock has a market cap of $2.03 billion, a PE ratio of 14.08, a P/E/G ratio of 0.87 and a beta of 0.78. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The business’s 50-day moving average price is $47.14 and its 200-day moving average price is $44.63.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AMPH. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price on the stock. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $60.33.

Insider Buying and Selling

In related news, EVP Yakob Liawatidewi sold 5,214 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the transaction, the executive vice president now directly owns 74,938 shares in the company, valued at $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the sale, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,533 shares of company stock valued at $1,676,542. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.